Cisplatin in advanced salivary gland carcinoma. A phase II study of 25 patients.
A prospective Phase II study was carried out to test cisplatin (CDDP) as a single agent in salivary gland carcinomas. CDDP was administered (100 mg/m2) every 3 weeks to 25 consecutive patients with either recurrent or locally advanced salivary gland carcinoma. Six patients had received prior chemotherapy, and the other patients had had only surgery or radiation therapy or no treatment at all. The response rate was 18% (95% confidence interval [CI], 6% to 41%). Response duration was between 5 and 9 months. Median overall survival time was 14 months. CDDP is a moderately active drug in salivary gland carcinomas. It should be included in multidrug regimens to be tested in prospective studies, which are difficult to carry out due to the rarity of these tumors.
Licitra
L
L
Division of Medical Oncology, Istituto Nazionale Tumori, Milan, Italy.
Marchini
S
S
Spinazzè
S
S
Rossi
A
A
Rocca
A
A
Grandi
C
C
Molinari
R
R
D000328:Adult; D000368:Aged; D002277:Carcinoma / Q000188:drug therapy* / Q000556:secondary; D002945:Cisplatin / Q000008:administration & dosage / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011446:Prospective Studies; D012074:Remission Induction; D012468:Salivary Gland Neoplasms / Q000188:drug therapy*; D015996:Survival Rate
D002945:Cisplatin